Home Cart 0 Sign in  

[ CAS No. 85622-93-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 85622-93-1
Chemical Structure| 85622-93-1
Structure of 85622-93-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 85622-93-1 ]

Related Doc. of [ 85622-93-1 ]

Alternatived Products of [ 85622-93-1 ]

Product Details of [ 85622-93-1 ]

CAS No. :85622-93-1 MDL No. :MFCD00866492
Formula : C6H6N6O2 Boiling Point : -
Linear Structure Formula :- InChI Key :BPEGJWRSRHCHSN-UHFFFAOYSA-N
M.W : 194.15 Pubchem ID :5394
Synonyms :
NSC 362856;CCRG 81045;Temodar. Foreign brand name: Temodal;TMZ. US brand names: Methazolastone;RP46161;SCH-52365;Temodal;Methazolastone;MB 39831;TMZ
Chemical Name :3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

Calculated chemistry of [ 85622-93-1 ]

Physicochemical Properties

Num. heavy atoms : 14
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.17
Num. rotatable bonds : 1
Num. H-bond acceptors : 5.0
Num. H-bond donors : 1.0
Molar Refractivity : 44.4
TPSA : 108.17 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -8.24 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.29
Log Po/w (XLOGP3) : -1.06
Log Po/w (WLOGP) : -2.08
Log Po/w (MLOGP) : -0.98
Log Po/w (SILICOS-IT) : -1.78
Consensus Log Po/w : -0.92

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.79
Solubility : 31.8 mg/ml ; 0.164 mol/l
Class : Very soluble
Log S (Ali) : -0.72
Solubility : 36.8 mg/ml ; 0.189 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.03
Solubility : 181.0 mg/ml ; 0.931 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.35

Safety of [ 85622-93-1 ]

Signal Word:Danger Class:9
Precautionary Statements:P201-P202-P261-P264-P270-P271-P273-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P308+P313-P332+P313-P337+P313-P403+P233-P405-P501 UN#:3077
Hazard Statements:H302-H315-H319-H335-H340-H350-H401-H411 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 85622-93-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 85622-93-1 ]
  • Downstream synthetic route of [ 85622-93-1 ]

[ 85622-93-1 ] Synthesis Path-Upstream   1~21

  • 1
  • [ 85622-93-1 ]
  • [ 53952-42-4 ]
  • [ 813-78-5 ]
  • [ 1455-13-6 ]
  • [ 53952-43-5 ]
  • [ 360-97-4 ]
Reference: [1] Journal of the Chemical Society, Chemical Communications, 1993, # 15, p. 1177 - 1178
  • 2
  • [ 624-83-9 ]
  • [ 7008-85-7 ]
  • [ 85622-93-1 ]
YieldReaction ConditionsOperation in experiment
76.5% at 50℃; EXAMPLE 3: Preparation of TMZ; 15 g of 5-diazo-5 H-imidazole-4 carboxamide was added to the flask containing methyl isocyanate absorbed in dioxane obtained in Example 2. The reaction mass was then heated to 500C and the temperature maintained for 15-18 hours until HPLC showed that the starting material had been consumed. The reaction mixture was then cooled to 300C and 8 ml of acidic water was added.The reaction mixture was stirred for 30 minutes. 60 ml of Ethyl acetate was added. The reaction mixture was stirred for 60 minutes and filtered. The solid obtained was washed with 15 ml of ethyl acetate and suction dried for 15 minutes. The solid was suspended in 45 ml of acetone and stirred for 30 minutes. The solid was filtered and suction dried for 15 minutes. The yield was 18g with a moisture content of 1percent. The corrected yield is 16.5g (78.5percent) with a purity of 99.74percent.
Reference: [1] Journal of Medicinal Chemistry, 1984, vol. 27, # 2, p. 196 - 201
[2] Patent: WO2010/58430, 2010, A1, . Location in patent: Page/Page column 14
[3] Bioorganic and Medicinal Chemistry Letters, 1996, vol. 6, # 2, p. 185 - 188
[4] Journal of Medicinal Chemistry, 2002, vol. 45, # 25, p. 5448 - 5457
[5] Patent: US2007/225496, 2007, A1, . Location in patent: Page/Page column 4-5
[6] Molecules, 2010, vol. 15, # 12, p. 9427 - 9436
  • 3
  • [ 188612-53-5 ]
  • [ 85622-93-1 ]
YieldReaction ConditionsOperation in experiment
64%
Stage #1: With acetic acid; lithium bromide In water at 20℃; for 1 h;
Stage #2: With sodium nitrite In water at -10 - 20℃; for 6 h;
Stage #3: With sodium thiosulfate In water for 0.333333 h;
Glacial acetic acid (25 ml), water (250 ml), LiBr (450 g) were charged and the contents20 were stirred for 30 minutes and cooled to room temperature. 5-Amino-l-(N-methyl carbamoyl) imidazole-4-carboxamide (II) (25 g) was added and stirred the contents for additional 30 minutes. The reaction mixture was cooled to 0°C and then added drop wise to NaNO2 solution (12.5 g in 50 ml water) at -10 to5 °C. The reaction mass was stirred for 1 hr at 0-5 °C and then at room temperature for 5 hrs. To this reaction mixture, sodium thiosulphate solution (25 g in25 250 ml of water) was added slowly and stirred for 20 minutes. This process yielded an acidic solution containing temozolomide. This acidic solution was extracted using dichloromethane (1000 ml) by continuous liquid-liquid extractor, concentrated to 100 ml stage and filtered to give temozolomide (16.9 g, 64percent yield, 99.4 percent HPLC purity).
47%
Stage #1: With sodium nitrite In water at 0℃; for 0.333333 h;
Stage #2: With tartaric acid In water at 0 - 60℃; for 4 h;
500 mL of water and 40 g of carbamoyl-AICA were added in a 2 liter reactor. The reaction mixture was cooled to 0 °C and 15.8 g of sodium nitrite was added. The resulting mixture was stirred for 20 minutes and then a solution of tartaric acid (34 g in 100 mL of water) was added slowly. The reaction mixture was stirred for 2 h at 0°C and then stirred at room temperature for 2 hours. The temperature was adjusted to 60 °C, and the suspension was filtered and the residue washed with hot water. Thefiltrate containing 60percent temozolomide and 40percentazahypoxanthine was acidified to pH 2-3, eluted through a resin with acidified aqueous solution and ethanol. The eluate was clarified through a carbon filter coupled to the column outlet, obtaining a solution of temozolomide with purity greater than 90percent (HPLC) . The obtained solution was concentrated at 60 °C and 25 mbar to between 30 and 40 volumes relative to the theoretical weight of temozolomide to achieve a suspension with fine crystals. The suspension was then cooled to 5-10 °C, stirred for 2 hours and filtered through Btichner funnel. The residue was washed with acidified water, and the collected crystals were dried under vacuum at 50 °C for 4 hours, providing 20g of temozolomide monohydrate as a white solid of 99.98percent purity (HPLC) e 47percent yield. DRXP (2) : 9.385, 11.863; 14.676; 16.826; 18.406; 18.565; 20.322; 28.232 ± 0.2° (Figure 1) IR (cm’) 3421; 3348; 1739; 1670; 1598; 1562; e 1408 (Figure 2).
43%
Stage #1: With acetic acid; lithium chloride In water at 20℃; for 1 h;
Stage #2: With sodium nitrite In water at -10 - 20℃; for 6 h;
Stage #3: With sodium thiosulfate In water for 0.333333 h;
Glacial acetic acid (25 ml), water (250 ml) and LiCl (225 g) were charged and the contents were stirred for 30 minutes and cooled to room temperature. 5-Amino-l-(N- methylcarbamoyl) imidazole-4-carboxamide (II) (25 g) was added and stirred the contents for further 30 minutes. The reaction mixture was cooled to 0°C and then added drop wise to NaNO2 solution (12.5 g in 50 ml water) at -10 to 5 °C. The reaction mass was stirred for 1 hr at 0-5 °C and then at room temperature for 5 hrs. To this reaction mixture, sodium thiosulphate solution (25 g in 250 ml of water) was added slowly and stirred for 20 minutes (solution A). This process yielded an acidic solution containing temozolomide.; Solution A as prepared above in Example 1 is extracted using dichloromethane (5.0 L x5), concentrated to 100 ml stage and filtered to give temozolomide (1 1.5 g, 43percent yield, 99.0 percent HPLC purity).; Solution A as prepared above in Example 1 is extracted using dichloromethane (1000 ml) by continuous liquid-liquid extractor, concentrated to 100 ml stage and filtered to give temozolomide (17.2 g, 65percent yield, 99.3 percent HPLC purity). ; Glacial acetic acid (50 ml), water (500 ml) and LiCl (450 g) were charged and the5 contents were stirred for 30 minutes and cooled to room temperature. 5-Amino-l-(N- methylcarbamoyl) imidazole-4-carboxamide (II) (50 g) was added and stirred the contents for further 30 minutes. The reaction mixture was cooled to 0°C and then added drop wise to NaNO2 solution (25 g in 100 ml water) at -10 to 5 °C. The reaction mass was stirred for 1 hr at 0-5 °C and then at room temperature for 5 hrs. To this reaction mixture, sodium thiosulphate solution10 (50 g in 500 ml of water) was added slowly and stirred for 20 minutes . This process yielded an acidic solution containing temozolomide. This acidic solution was extracted using hexane (2000 ml) by continuous liquid-liquid extractor, concentrated to 100 ml stage and filtered to give temozolomide (33.4 g, 63percent yield, 99.2 percent HPLC purity).; Glacial acetic acid (50 ml), water (500 ml) and LiCl (450 g) were charged and the contents were stirred for 30 minutes and cooled to room temperature. 5-Amino-l-(N- methylcarbamoyl) imidazole-4-carboxamide (II) (50 g) was added and stirred the contents for further 30 minutes. The reaction mixture was cooled to 0°C and then added drop wise to sodium nitrite solution (25 g in 100 ml water) at -10 to 5 °C. The reaction mass was stirred for 1 hr at 0- 5 °C and then at room temperature for 5 hrs. To this reaction mixture, sodium thiosulphate solution (50 g in 500 ml of water) was added slowly and stirred for 20 minutes. This process yielded an acidic solution containing temozolomide. This acidic solution was extracted using dichloromethane (2000 ml) by continuous liquid-liquid extractor, concentrated to 100 ml stage and filtered the temozolomide.To the above filtered temozolomide, acetone (350 ml) was charged at room temperature, heated to reflux (52-55°C) and maintained for 5 hours, distilled off 50percent of acetone atmospherically at 52-550C, charged acetone (175 ml) and distilled off 50percent of acetone atmospherically at 52-550C, this process was repeated twice and 25percent of aqueous acetone (350 ml, pH of water is acidified to 3.0 using acetic acid) was charged at 520C. Refluxed the contents for 1 hour at 52°C, slowly cooled to room temperature in 1 hour and maintained at room temperature for 2 hours. Chilled the contents to 100C, maintained for 1 hour, filtered the solid, washed with acetone (35 ml) and dried at 45-500C under vacuum to yield temozolomide (33.2 g, 62percent yield, 99.8percent HPLC purity, dichloromethane content : 250 ppm ).
1.5 g
Stage #1: With acetic acid; sodium nitrite In water at -5 - 5℃; for 2 h;
Stage #2: With calcium chloride In water at 20℃; for 2 h; Cooling with ice
To a stirred suspension of 5-amino-N 1-methyl-i I-{-imidazole- 1, 4- dicarboxamide (5g. 0.0272 mol) and acetic acid (4.5 mE) was added sodium nitrite (2.5g, 0.0362 moi) in water (5.0 L) at -5 to 0°C at a rate so that temperature does not rise above 0-5°C. The reaction mixture was stirred at 0-5°C for 2h. After consumption of starting material, ice bath was removed and calcium chloride (12.5 g) was added to the reaction mixture and stirred at room temperature for another two hours. The reaction mass was extracted with a 2.5percent solution of dimethyl sulfoxide in dichloromethane (5 X 500 mL), Combined organic layer was dried over sodium sulfate and the solvent was distilled below 40°C. After removing the dichioromethane completely, the dimethyl sulfoxide suspension was cooled to 10-20°C and filtered the solid. The solid was washed with ethyl acetate (15 mE) and dried at room temperature. The obtained solid was siurried in ethyl acetate (40 mE) and heated at 40-45°C for lh. The solid was filtered and dried at room temperature to yield Temozolomide (1 .5g) as an off white solid.11*JMR (DMSO-d6): 5 8.81 (s, 1H), 7,78 (bs, 1H), 7.66 (bs, 1H), 3.86 (s, 3H); Mass (m/z):194.8 (M+);HPLC purity: 99.6 1percent.

Reference: [1] Patent: WO2008/38031, 2008, A1, . Location in patent: Page/Page column 9
[2] Patent: WO2018/112589, 2018, A1, . Location in patent: Paragraph 057
[3] Patent: WO2008/38031, 2008, A1, . Location in patent: Page/Page column 5; 8-9; 10
[4] Patent: WO2010/140168, 2010, A1, . Location in patent: Page/Page column 16-17
[5] Patent: WO2018/122724, 2018, A1, . Location in patent: Page/Page column 12
  • 4
  • [ 442534-20-5 ]
  • [ 85622-93-1 ]
YieldReaction ConditionsOperation in experiment
52% at 15 - 20℃; for 3 h; The compound TZ-6 (25,0 g, 0,10 mol) was added portionwise to stirred sulfuric acid (d 1.8, 70 mL) at 15–25 °C. The whole mixture was stirred at ambient temperature for 3 h and then poured into 96percent ethanol (800 mL) at 0 °C. The suspension was stirred for 30 min. at 0 °C, the precipitate collected, washed with cold ethanol (50 mL) and dried on air for 16 h. The obtained crude TZ-7 was dissolved in the refluxed mixture of acetone (450 mL), water (150 mL) and acetic acid (38 mL), the solution was filtered, the filtrate refluxed again, cooled to ambient temperature and stirred for 4 h. The precipitate was then collected, washed with acetone/water 3:1 (80 mL) and dried in vacuo for 16 h at 25 °C to afford 10.1 g (52percent) of pharmaceutically pure TZ-7. Elementary analysis: 36.99percent (C), 3.00percent (H), 43.02percent (N). ESI-MS: calcd. for (M+H)+: 194.06, found 194.06.
Reference: [1] Molecules, 2013, vol. 18, # 12, p. 15344 - 15356
  • 5
  • [ 74-88-4 ]
  • [ 85622-93-1 ]
Reference: [1] Patent: WO2011/107726, 2011, A1, . Location in patent: Page/Page column 53
[2] Organic Letters, 2012, vol. 14, # 23, p. 5872 - 5875
  • 6
  • [ 1161825-88-2 ]
  • [ 74-88-4 ]
  • [ 85622-93-1 ]
YieldReaction ConditionsOperation in experiment
22% With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetonitrile Synthesis 363-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-c/J[1 ,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide); 1 ,8-Diazabicycloundec-7-ene (DBU) (35 μL, 0.228 mmol, 1.2 eq.) was added dropwise to a suspension of the hydroxymethyl derivative of Temozolomide (3-(hydroxymethyl)-4-oxo- 3,4-dihydroimidazo[5,1-cfl[1,2,3,5]tetrazine-8-carboxamide) (40 mg, 0.19 mmol) and iodomethane (2 M solution in tert-butylmethyl ether, 238 μL, 0.475 mmol, 2.5 eq.) in <n="94"/>acetonitrile (1 ml_). The resulting green suspension became homogeneous and was stirred overnight. The reaction was acidified with 1 N HCI and the yellow solution was extracted four times with ethyl acetate. The combined organic extracts were washed with water and then dried over MgSO4. The solvent was removed under vacuum to give 8 mg of the title compound as a yellow solid (22percent crude). The NMR data of the crude product were consistent with the NMR data of temozolomide. 1H NMR (DMSO d6): 8.22 (s, 1H), 7.81 (S1 1H), 7.68 (s, 1H)1 3.87 (S1 3H). LCMS: 91percent pure; m/z: 217.4 (M+Na+).
Reference: [1] Patent: WO2009/77741, 2009, A2, . Location in patent: Page/Page column 92-93
[2] MedChemComm, 2018, vol. 9, # 3, p. 545 - 553
  • 7
  • [ 72-40-2 ]
  • [ 7693-46-1 ]
  • [ 85622-93-1 ]
Reference: [1] Patent: US2002/133006, 2002, A1,
  • 8
  • [ 865071-35-8 ]
  • [ 624-83-9 ]
  • [ 85622-93-1 ]
Reference: [1] Patent: US2012/108811, 2012, A1, . Location in patent: Page/Page column 4
  • 9
  • [ 188612-53-5 ]
  • [ 85622-93-1 ]
  • [ 4656-86-4 ]
Reference: [1] Chemical Communications, 1997, # 4, p. 363 - 364
  • 10
  • [ 188612-53-5 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of Organic Chemistry, 1997, vol. 62, # 21, p. 7288 - 7294
  • 11
  • [ 157467-00-0 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society - Series Chemical Communications, 1994, # 14, p. 1687 - 1688
[2] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1995, # 21, p. 2783 - 2789
  • 12
  • [ 77-78-1 ]
  • [ 85622-93-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1996, vol. 6, # 2, p. 185 - 188
  • 13
  • [ 1332700-58-9 ]
  • [ 85622-93-1 ]
Reference: [1] Organic Letters, 2012, vol. 14, # 23, p. 5872 - 5875
  • 14
  • [ 196806-10-7 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of Organic Chemistry, 1997, vol. 62, # 21, p. 7288 - 7294
  • 15
  • [ 157466-98-3 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1995, # 21, p. 2783 - 2789
[2] Journal of the Chemical Society - Series Chemical Communications, 1994, # 14, p. 1687 - 1688
  • 16
  • [ 157466-97-2 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1995, # 21, p. 2783 - 2789
[2] Journal of the Chemical Society - Series Chemical Communications, 1994, # 14, p. 1687 - 1688
  • 17
  • [ 157466-99-4 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1995, # 21, p. 2783 - 2789
[2] Journal of the Chemical Society - Series Chemical Communications, 1994, # 14, p. 1687 - 1688
  • 18
  • [ 1025840-09-8 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society. Perkin Transactions 1, 2002, # 16, p. 1877 - 1880
  • 19
  • [ 157466-96-1 ]
  • [ 85622-93-1 ]
Reference: [1] Journal of the Chemical Society - Series Chemical Communications, 1994, # 14, p. 1687 - 1688
  • 20
  • [ 530-62-1 ]
  • [ 85622-93-1 ]
Reference: [1] Patent: WO2018/112589, 2018, A1,
  • 21
  • [ 85622-93-1 ]
  • [ 113942-30-6 ]
YieldReaction ConditionsOperation in experiment
98.6% at 15 - 20℃; Example 1 Preparation of TMZ acid (EP0252682) TMZ (2.577mmol, 0.5g) was mixed with concentrated sulfuric acid (4ml) with agitation. Sodium nitrite (9.4mmol, 0.65g) was dissolved in 2.6ml of water and then dropped into aforementioned mixture on an ice bath at temperature of below 15°C, to stir at room temperature overnight. The resulting mixture continued to be added with 10g of ice and cool for 1 hour in ice-bath. The solid product was colleted by filtration, and dried in vacuo to give 0.493g of TMZ acid. The yield was 98.6percent.
75% With sulfuric acid; sodium nitrite In water at 0 - 20℃; for 17 h; Inert atmosphere; Darkness TMZ-carboxylic acid (shown as compound 1 in FIG. 1) was prepared following a previously described procedure. See, e.g., Arrowsmith, J.; Jennings, S. A.; Langnel, D. A. F.; Wheelhouse, R T.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 39. Synthesis of Bis(Imidazotetrazines) with Saturated Space Groups. J. Chem. Soc., Perkin Trans. 2000, 1, 4432-4438. In a round bottom flask charged with a stir bar and fitted with an addition funnel, TMZ (2.29 grams, 11.8 millimoles) was dissolved in concentrated H2504 (23.6 milliliters), and the resulting yellow solution was cooled at 0° C. under nitrogen. A solution of sodium nitrite (2.51 grams, 36.4 millimoles) in water (23.6 milliliters) was then added drop-wise over 45 minutes, noting the evolution of a brown gas during addition. The mixture was allowed to warm to room temperature and was stirred under nitrogen, protected from light. After stirring for 17 hours, the solution was cooled at 0° C., and the reaction was quenched with ice (61.26 grams). Further stirring at 0° C. resulted in the precipitation of 1 as a fine white solid, which was isolated by vacuum filtration, washed with cold water, and dried under high vacuum to afford 1 in 75percent yield. 1H-NMR (500 MHz, DMSO-d6, δ, ppm): 3.88 (s, 3H), 8.82 (s, 1H), 13.33 (br, 1H). 13C-NMR (125 MHz, DMSO-d6, δ, ppm): 36.32, 127.78, 129.09, 136.48, 139.10, 161.85. HRMS-EI (m/z): [M]+ calculated for C6H5N5O3: 195.0392, found: 195.0395.
Reference: [1] European Journal of Medicinal Chemistry, 2002, vol. 37, # 4, p. 323 - 332
[2] Patent: EP1798234, 2007, A1, . Location in patent: Page/Page column 11
[3] Patent: US2018/79754, 2018, A1, . Location in patent: Paragraph 0082; 0101-0102
[4] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 691 - 702
[5] Journal of Medicinal Chemistry, 2002, vol. 45, # 25, p. 5458 - 5470
[6] Molecules, 2010, vol. 15, # 12, p. 9427 - 9436
[7] International Journal of Molecular Sciences, 2018, vol. 19, # 2,
Same Skeleton Products
Historical Records